drugset / Trial / NCT01954017

STP206 for the Prevention of Necrotizing Enterocolitis (NEC)

NCT01954017 ↗

Phase 1 Completed 103 enrolled Leadiant Biosciences, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is a sequential dose escalation study to assess the safety, tolerability, and preliminary NEC-preventative efficacy of two doses of STP206 versus control in very low birth weight and extremely low birth weight neonates.

Timeline

Start
2014-01-30
Primary completion
2018-02-28
Completion
2018-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject STP206 Other / unclassified — —